Please assess the completion status of the following clinical trial:

Trial Title: Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia, schizoaffective disorder (depressed type), or schizophreniform disorder~* First major episode of psychotic symptoms occurred within 2 years prior to study entry~Exclusion Criteria:~* Neurological disorder or injury (e.g., encephalitis, epilepsy, traumatic brain injury)~* Mental retardation (e.g., premorbid intelligence quotient (IQ) less than 70)~* Significant alcohol or substance use during last 6 months~* Unable to complete research measures in English~* Any condition that may make risperidone use medically inadvisable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cog Remediation, risperidone injection (Type: EXPERIMENTAL): Participants will receive cognitive remediation training plus risperidone, administered via injection.
- Healthy Behavior Training, risperidone injection (Type: ACTIVE_COMPARATOR): Participants will receive health behavior training plus risperidone, administered via injection.
- Cog Remediation, oral risperidone (Type: EXPERIMENTAL): Participants will receive cognitive remediation training plus risperidone administered orally.
- Healthy Behavior Training, oral risperidone (Type: ACTIVE_COMPARATOR): Participants will receive health behavior training plus risperidone administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).